Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
Cheng Zhang, … , Payal Kapur, Qing Zhang
Cheng Zhang, … , Payal Kapur, Qing Zhang
Published April 15, 2024
Citation Information: J Clin Invest. 2024;134(8):e175703. https://doi.org/10.1172/JCI175703.
View: Text | PDF
Research Article Oncology

Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis

  • Text
  • PDF
Abstract

N6-Methyladenosine (m6A) is the most abundant posttranscriptional modification, and its contribution to cancer evolution has recently been appreciated. Renal cancer is the most common adult genitourinary cancer, approximately 85% of which is accounted for by the clear cell renal cell carcinoma (ccRCC) subtype characterized by VHL loss. However, it is unclear whether VHL loss in ccRCC affects m6A patterns. In this study, we demonstrate that VHL binds and promotes METTL3/METTL14 complex formation while VHL depletion suppresses m6A modification, which is distinctive from its canonical E3 ligase role. m6A RNA immunoprecipitation sequencing (RIP-Seq) coupled with RNA-Seq allows us to identify a selection of genes whose expression may be regulated by VHL-m6A signaling. Specifically, PIK3R3 is identified to be a critical gene whose mRNA stability is regulated by VHL in a m6A-dependent but HIF-independent manner. Functionally, PIK3R3 depletion promotes renal cancer cell growth and orthotopic tumor growth while its overexpression leads to decreased tumorigenesis. Mechanistically, the VHL-m6A–regulated PIK3R3 suppresses tumor growth by restraining PI3K/AKT activity. Taken together, we propose a mechanism by which VHL regulates m6A through modulation of METTL3/METTL14 complex formation, thereby promoting PIK3R3 mRNA stability and protein levels that are critical for regulating ccRCC tumorigenesis.

Authors

Cheng Zhang, Miaomiao Yu, Austin J. Hepperla, Zhao Zhang, Rishi Raj, Hua Zhong, Jin Zhou, Lianxin Hu, Jun Fang, Hongyi Liu, Qian Liang, Liwei Jia, Chengheng Liao, Sichuan Xi, Jeremy M. Simon, Kexin Xu, Zhijie Liu, Yunsun Nam, Payal Kapur, Qing Zhang

×

Figure 6

VHL regulates PIK3R3 mRNA stability in an m6A dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
VHL regulates PIK3R3 mRNA stability in an m6A dependent manner.
(A–D) PI...
(A–D) PIK3R3 mRNA levels were measured by qPCR in the cells transfected with indicated vectors and treated with Actinomycin D (5 μg/mL) for indicated time. (E) Schematic diagram of PIK3R3 3′ UTR WT and mutant luciferase reporter. (F–M) Relative luciferase activity of PIK3R3 3′ UTR WT or mutant in HKC cells transfected with indicated vectors. (N–P) qPCR analysis of IGF2BP1/2/3 and PIK3R3 mRNA levels in indicated HKC cell lines transfected with Ctrlsi or IGF2BP1/2/3siRNAs. (Q) PIK3R3 mRNA levels were measured by qPCR in HKC cells after treatment with Actinomycin D (normalized to 0 hours). (R and S), Anti-Flag RIP qPCR test the interaction between PIK3R3 mRNA and IGF2BP1 (R) or IGF2BP2(S). Data show mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA (A–D and Q), 1-way ANOVA analysis (F–I, N–P, R, and S) or unpaired t test (J–P).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts